Table 2. Characteristics of eligible studies.

Trials	Sample sizes		Age range		Drug type		Dosage and frequency		Crossover from control group to experimental group
	Experiment	control	Experiment	control	Experiment	control	Experiment	control
OlympiAD	205	97	22–76	24–68	Olaparib	PTC	300 mg twice daily	standard therapy: eribulin mesylate administered intravenously at a dose of 1.4 mg on day 1 and day 8, repeated every 21 days; or vinorelbine administered intravenously at a dose of 30 mg on day 1 and day 8, repeated every 21 days.	not permitted
EMBRACA	287	144	27–84	24–88	Talazoparib	PTC	1 mg orally once daily continuously	standard-therapy: capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles	not permitted

PTC: Standard-Therapy Group.